



SAFETY DATA SHEET

Revision date: 03-Nov-2014

Version: 2.0

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Trimebutine, ruscogenin suppositories

Trade Name: PROCTOLOG; DEBRIDAT

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as hemorrhoidal treatment

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Additional Information:

For a more detailed discussion of potential health hazards and toxicity see Section 11.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Trimebutine, ruscogenin suppositories
Revision date: 03-Nov-2014

Page 2 of 6
Version: 2.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Trimebutine maleate	34140-59-5	251-845-9	Not Listed	Not Listed	120 mg

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Ruscogenin	472-11-7	207-447-2	Not Listed	Not Listed	10mg***
Semi-synthetic glycerides	MIXTURE	Not Listed	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

SAFETY DATA SHEET

Material Name: Trimebutine, ruscogenin suppositories
Revision date: 03-Nov-2014

Page 3 of 6
Version: 2.0

6. ACCIDENTAL RELEASE MEASURES

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Spills should be handled by vacuuming or wet mopping. Transfer all waste to a labeled container and move it to a secure holding area. Clean spill area thoroughly. Prevent discharge to drains.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Trimebutine maleate

Pfizer OEL TWA-8 Hr: 1000µg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

SAFETY DATA SHEET

Material Name: Trimebutine, ruscogenin suppositories
Revision date: 03-Nov-2014

Page 4 of 6
Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Suppository	Color:	White or creamy-white
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Trimebutine maleate

No data available

Ruscogenin

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	None known

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Short Term:	An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8).
Long Term:	Based on its pharmacologic properties and findings in animal studies, this compound may cause gastrointestinal system
Known Clinical Effects:	Adverse effects associated with therapeutic use of trimebutine are infrequent and include skin rash, sleepiness, headache, vomiting, and dizziness .

SAFETY DATA SHEET

Material Name: Trimebutine, ruscogenin suppositories
Revision date: 03-Nov-2014

Page 5 of 6
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Trimebutine maleate

Rat Oral LD50 > 5000 mg/kg

Mouse Oral LD50 3230mg/kg

Rat IP LD50 365mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Trimebutine maleate

Reproductive & Fertility Rat Oral 1000 mg/kg/day NOAEL No effects at maximum dose

Reproductive & Fertility Rabbit Oral 1000 mg/kg/day NOAEL No effects at maximum dose

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Trimebutine, ruscogenin suppositories
Revision date: 03-Nov-2014

Page 6 of 6
Version: 2.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Trimebutine maleate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	251-845-9

Ruscogenin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	207-447-2

Semi-synthetic glycerides

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

16. OTHER INFORMATION

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 11 - Toxicology Information. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage.
Revision date:	03-Nov-2014 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet